Fortress Biotech Announces Launch of Proposed Public Offering
November 09, 2023 17:05 ET
|
Fortress Biotech, Inc.
MIAMI, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and...
Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1
October 16, 2023 09:00 ET
|
Fortress Biotech, Inc.
Recent $11.3 million grant from the California Institute for Regenerative Medicine (CIRM) intended to fund the Phase 1 clinical trial at City of Hope; the Investigational New Drug application for...
Fortress Biotech Announces Reverse Stock Split
October 09, 2023 12:50 ET
|
Fortress Biotech, Inc.
MIAMI, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and...
Fortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference
October 05, 2023 08:30 ET
|
Fortress Biotech, Inc.
Fortress Biotech will present at the ROTH MKM 2023 Healthcare Opportunities Conference in New York City on Thursday, October 12, 2023, at 11:00 a.m. ET.
Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 07, 2023 08:30 ET
|
Fortress Biotech, Inc.
MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...
Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
August 14, 2023 16:01 ET
|
Fortress Biotech, Inc.
Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023 Positive topline results from two Phase 3 clinical trials...
Fortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023
August 03, 2023 08:30 ET
|
Fortress Biotech, Inc.
MIAMI, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...
Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States
June 29, 2023 08:00 ET
|
Fortress Biotech, Inc.
Data from Phase 1 clinical trial in healthy volunteers show comparable pharmacokinetic, pharmacodynamic and safety profile between U.S. and Japanese healthy subjects Initiating Phase 1b clinical...
Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program
June 15, 2023 08:00 ET
|
Fortress Biotech, Inc.
Multicenter randomized placebo-controlled trials will evaluate the ability of the cytomegalovirus (“CMV”) vaccine to enhance protective virus-specific immunity in stem cell donors to reduce the risk...
Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
May 15, 2023 16:01 ET
|
Fortress Biotech, Inc.
Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in second half of 2023 PDUFA goal date of January 3, 2024 set by FDA for cosibelimab to treat metastatic...